{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:25Z","timestamp":1786120285955,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"DOI":"10.1097\/qai.0b013e31824e5256","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T21:57:38Z","timestamp":1329515858000},"page":"314-320","source":"Crossref","is-referenced-by-count":25,"title":["Treatment Outcomes of Recommended First-Line Antiretroviral Regimens in Resource-Limited Clinics"],"prefix":"10.1097","volume":"60","author":[{"given":"Anthony","family":"Amoroso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Etienne-Mesubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Edozien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Ojoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sheneberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Obiefune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian Bazle","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-16-20210131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/QAI.0b013e3181c6c65c","article-title":". Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.","volume":"54","author":"Chi","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-16-20210131","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1310\/hct1005-320","article-title":". Viral load decay in antiretroviral-naive patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine.","volume":"10","author":"Amoroso","year":"2009","journal-title":"HIV Clin Trials"},{"key":"R6-16-20210131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.qai.0000191997.70034.80","article-title":". Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.","volume":"41","author":"Droste","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-16-20210131","first-page":"CD008740","article-title":"Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals.","volume":"6","author":"Spaulding","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-16-20210131","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3851\/IMP1803","article-title":". Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.","volume":"16","author":"Gathe","year":"2011","journal-title":"Antivir Ther"},{"key":"R9-16-20210131","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/2047-783X-14-12-516","article-title":". Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week Prospective Multicenter Study (TENOR-Trial).","volume":"14","author":"Weberschock","year":"2009","journal-title":"Eur J Med Res"},{"key":"R10-16-20210131","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1258\/ijsa.2010.010258","article-title":". Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.","volume":"22","author":"Smith","year":"2011","journal-title":"Int J STD AIDS"},{"key":"R11-16-20210131","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":". Nevirapine versus atazanavirritonavir, each combined with tenofovir disoproxil fumarateemtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir Ther"},{"key":"R12-16-20210131","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1742-1241.2011.02807.x","article-title":". A randomised comparison of safety and efficacy of nevirapine vs. atazanavirritonavir combined with tenofoviremtricitabine in treatment-naive patients.","volume":"65","author":"Dejesus","year":"2011","journal-title":"Int J Clin Pract"},{"key":"R13-16-20210131","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/QAD.0b013e3283322895","article-title":". Safety and efficacy of tenofoviremtricitabine plus nevirapine in HIV-infected patients.","volume":"24","author":"Labarga","year":"2010","journal-title":"AIDS"},{"key":"R14-16-20210131","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/591802","article-title":"Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.","volume":"47","author":"Redfield","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R17-16-20210131","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/529394","article-title":". Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.","volume":"46","author":"Lapadula","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R18-16-20210131","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dkn471","article-title":". High rate of early virological failure with the once-daily tenofovirlamivudinenevirapine combination in naive HIV-1-infected patients.","volume":"63","author":"Rey","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R21-16-20210131","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1310\/M47B-R51C-X0MC-K3GW","article-title":". Comparison of nevirapine and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study.","volume":"3","author":"Keiser","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R22-16-20210131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e3282f3cc35","article-title":". Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.","volume":"22","author":"Bannister","year":"2008","journal-title":"AIDS"},{"key":"R23-16-20210131","first-page":"24","article-title":". Nevirapine or efavirenz in combination with two nucleoside analogues in HIV infected antiretroviral naive patients.","volume":"20","author":"Gaytan","year":"2004","journal-title":"Med Intern Mex"},{"key":"R24-16-20210131","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1310\/0CJ5-2ABQ-CB00-6MR6","article-title":". SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.","volume":"3","author":"Nunez","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R25-16-20210131","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/QAD.0b013e328310407e","article-title":". Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.","volume":"22","author":"Nachega","year":"2008","journal-title":"AIDS"},{"key":"R26-16-20210131","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1310\/hct0905-324","article-title":"M, Hullsiek KH, Peng G, et al.. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.","volume":"9","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R27-16-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":". Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R30-16-20210131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudinelamivudine and efavirenz in antiretroviral-naive patients virologic, immunologic, and morphologic changesa 96-week analysis.","volume":"43","author":"Pozniak","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-16-20210131","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":". Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudinelamivudine and efavirenz in treatment-naive patients: 144-week analysis.","volume":"47","author":"Arribas","year":"2008","journal-title":"J Acquir ImmuneDefic Syndr"},{"key":"R32-16-20210131","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/428588","article-title":"Predictors of residual viremia in HIV infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.","volume":"191","author":"Havlir","year":"2005","journal-title":"J Infect Dis"},{"key":"R33-16-20210131","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/QAD.0b013e3283427de3","article-title":". Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copyml.","volume":"25","author":"Haim-Boukobza","year":"2011","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201207010-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:38:53Z","timestamp":1786048733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201207010-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31824e5256","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7,1]]}}}